inhibitor

(redirected from aromatase inhibitor)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Antonyms for inhibitor

a substance that retards or stops an activity

References in periodicals archive ?
With this approval, Ibrance is the first and only CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of men with HR+, HER2- metastatic breast cancer in the US.
Keywords: Anastrozole, Aromatase inhibitors, Breast cancer, Serum estrogen level.
However, given the previously discussed data, after oophorectomy, aromatase inhibitors are the preferred treatment option, and tamoxifen can be avoided.
Masculinization of female golden rabbitsh Siganus guttatus using an aromatase inhibitor treatment during sex differentiation.
Key clinical point: Aromatase inhibitors don't help shorter boys grow taller.
Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.
Risk was comparable in women on aromatase inhibitors (AIs) only and in those who used sequential tamoxifen followed by an AI, Reina Haque, Ph.D., reported at the San Antonio Breast Cancer Symposium.
This drug is non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis and anti-tumour agent available in market for breast cancer treatment.
She also notes that the risk reduction seen was not as much as seen with fellow aromatase inhibitor exemestane (Aromasin) in a previous study.
We aim to determine the efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss (AIBL) in postmenopausal women with early breast cancer.
All had been treated with an aromatase inhibitor, a type of drug that blocks estrogen production.
In the present study, masculinization of undifferentiated yellow catfish was induced by administration of the aromatase inhibitor (AI) letrozol (LZ).
Method: In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both).
To circumvent this, we used hippocampal organotypic cultures treated with the aromatase inhibitor, letrozole.